LLY

Business Context and Reporting Period

Company: Eli Lilly & Co.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2007
Business Overview: Eli Lilly operates primarily in the pharmaceutical products segment, with a smaller animal health segment. The company focuses on the development, manufacture, and marketing of pharmaceutical products for humans and animals.

Key Financial Metrics

All figures in millions of dollars, except per-share data.

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 20% in Q2 and 17% YTD compared to 2006. Growth was driven by volume increases, price increases, favorable exchange rates, and the full inclusion of Cialis sales following the acquisition of ICOS Corporation.
• Profitability Decline: Net income decreased 19% in Q2 and 29% YTD. This decline was primarily due to significant non-cash charges for acquired in-process research and development (IPR&D) totaling $328.1 million in Q2 and $656.6 million YTD, related to the acquisitions of ICOS, Hypnion, and Ivy Animal Health.
• Acquisitions:
  • ICOS Corporation: Acquired Jan 29, 2007, for ~$2.3 billion. Brought full ownership of Cialis.
  • Hypnion & Ivy: Acquired in Q2 2007 for $444.1 million combined.
• Debt Increase: Total debt increased by $1.32 billion from year-end 2006, primarily due to borrowings used to finance the ICOS acquisition.

Guidance, Outlook, and Risks

Management Guidance (2007 Full Year)

• Earnings Per Share: Raised guidance to a range of $2.75 to $2.85.
• Q3 EPS: Expected to be between $0.85 and $0.87.
• Sales Growth: Expected to be in the mid-teens percentage-wise.
• Operating Expenses: Expected to grow in the mid-teens, driven by full inclusion of Cialis expenses and increased R&D/marketing investments.

Key Risks and Contingencies

• Zyprexa Litigation:
  • Patent Challenges: Facing generic challenges in the U.S. (Supreme Court review pending), Canada (generic entry permitted in some provinces), and Germany (patent ruled invalid, appeal pending). An unfavorable outcome could materially impact results.
  • Product Liability: Approximately 30,200 claims settled (totaling ~$1.2 billion in prior charges). Approximately 540 claims remain unresolved. A tentative trial date is set for October 2007.
  • Government Investigations: Under investigation by the U.S. Attorney's Office and approximately 30 state attorneys general regarding marketing practices and Medicaid reporting. Potential for fines or penalties exists.
• Other Patent Litigation: Ongoing disputes regarding Evista and Gemzar patents with generic manufacturers (Barr, Teva, Sicor, etc.).
• Insurance Disputes: Carriers are contesting coverage for Zyprexa product liability claims; the company is largely self-insured for future losses.

Investor Verification Checklist

• Acquisition Accounting: Verify the final allocation of purchase price for ICOS, Hypnion, and Ivy, specifically the valuation of goodwill and intangible assets.
• Zyprexa Patent Status: Monitor the outcome of the U.S. Supreme Court review and the appeals in Canada and Germany, as generic entry would significantly impact future revenue.
• Product Liability Reserves: Review the adequacy of reserves for the remaining ~540 Zyprexa claims and the outcome of the October 2007 trial.
• Government Investigations: Track the status of the multi-state investigation into marketing practices and potential financial penalties.
• Cash Flow vs. Debt: Assess the company's ability to service the increased debt load ($5.04 billion) while funding R&D and litigation costs, given the reduction in cash balances.